0 0 -0.00610287707061898 -0.00878546039836364 -0.0140835624706592 -0.00414794447052519 -0.00160954999664683 0.00352089061766485
Sign Up Today X
Thanks for submitting the form.
Stockreport

3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
complex biomarker-driven oncology trials for Gilead Sciences, Kite Pharma, and emerging biotech companies SOUTH SAN FRANCISCO, Calif., March 02, 2026 BUSINESS WIRE )--3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Rebeca Villarreal-Barragan, MBA, as head of clinical operations. In this role, Ms. Villarreal-Barragan will lead all aspects of clinical operations as the company advances its pipeline of T-cell receptor (TCR)-based therapeutics for solid tumors. "Rebeca brings a strong track record of building and leading clinical operations in both established biopharma organizations and emerging biotechnology companies," said Behzad Kharabi, M.D., chief medical officer of 3T Biosciences. "Her pragmatic, quality-focused approach and experience delivering complex early phase clinical trials will be an important asset as we progress our pipeline of TCR-based therapeutics for [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
complex biomarker-driven oncology trials for Gilead Sciences, Kite Pharma, and emerging biotech companies SOUTH SAN FRANCISCO, Calif., March 02, 2026 BUSINESS WIRE )--3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Rebeca Villarreal-Barragan, MBA, as head of clinical operations. In this role, Ms. Villarreal-Barragan will lead all aspects of clinical operations as the company advances its pipeline of T-cell receptor (TCR)-based therapeutics for solid tumors. "Rebeca brings a strong track record of building and leading clinical operations in both established biopharma organizations and emerging biotechnology companies," said Behzad Kharabi, M.D., chief medical officer of 3T Biosciences. "Her pragmatic, quality-focused approach and experience delivering complex early phase clinical trials will be an important asset as we progress our pipeline of TCR-based therapeutics for [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS